Martin H. Huber Jr. - 01 Jan 2023 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
PRESIDENT AND HEAD OF R&D
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
01 Jan 2023
Net transactions value
$0
Form type
4
Filing time
04 Jan 2023, 15:11:57 UTC
Previous filing
23 Jun 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +136,500 $0.000000 136,500 01 Jan 2023 Common Stock 136,500 $2.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on January 1, 2023 and shall vest on February 1, 2023 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until January 1, 2027.